Liraglutide: products and studies

Identify the product

Liraglutide is the active ingredient in Saxenda and Victoza. Both labels describe prefilled pens for once-daily subcutaneous injection. The daily cadence differs from weekly injectable medicines in this class.

Saxenda has a weight-management indication. Victoza has type 2 diabetes and specified cardiovascular indications. The labels define different eligible populations and dose schedules. A shared ingredient does not make the products interchangeable treatment plans.

What SCALE measured

SCALE Obesity and Prediabetes compared daily liraglutide injections with placebo over 56 weeks in 3,731 adults without type 2 diabetes. Participants had obesity, or overweight with hypertension or dyslipidemia. Both groups received lifestyle counseling.

Mean weight loss was 8.4 kg with liraglutide versus 2.8 kg with placebo. The analysis used the last available observation to fill missing values. That approach and the selected population limit what the average can tell an individual. Nausea and diarrhea were common. This trial did not compare Saxenda with Victoza as competing personal regimens.

Record the prescribed plan

A useful record identifies the exact brand or generic product, indication, pen strength, prescribed amount and unit, daily timing, and prescriber. Preserve the clinician's written instructions for missed doses, interruptions, and follow-up. Record what happened rather than filling a missed log with an assumed administration.

Track symptoms and relevant measurements requested by the clinician. Include other glucose-lowering medicines in the medication history. The product labels include contraindications and warnings that require individual review. A study result or a chart cannot choose a product, change its amount, or decide when to restart it.